官宣9款医疗险覆盖商保创新药后又撤销 复星联合健康保险缘何“悔棋”

Core Viewpoint - The announcement by Fosun United Health Insurance regarding the inclusion of nine medical insurance products in the commercial health insurance innovative drug directory was retracted shortly after its release, raising questions about the internal decision-making process and the implications for the health insurance market [1][2]. Group 1: Announcement and Withdrawal - Fosun United Health Insurance initially announced that nine of its medical insurance products would cover drugs listed in the newly released commercial health insurance innovative drug directory [1]. - The announcement was later deleted from their official WeChat account, with the company stating that the details of the products had not been finalized, leading to the retraction [2]. Group 2: Market Implications - The release of the commercial health insurance innovative drug directory, which includes 19 high-value innovative drugs, is seen as a potential opportunity to enhance the purchasing rate of commercial insurance [4]. - The inclusion of innovative drugs in medical insurance is expected to significantly reduce the financial burden on patients and encourage pharmaceutical companies to invest in research and development [3][5]. Group 3: Challenges and Opportunities - The main challenges for insurance companies include the lack of historical data for accurate pricing and the risk of high claims due to expensive drugs [5]. - Successful integration of innovative drugs into insurance products requires effective risk management and collaboration with pharmaceutical companies to develop precise products and services [5]. Group 4: Company Performance and Capitalization - Fosun United Health Insurance, established in 2017, has shown a trend of profitability since 2021, with net profits reported at 0.20 billion, 0.63 billion, 0.23 billion, and 0.42 billion from 2021 to 2024 [6][7]. - The company recently received approval for a capital increase of 3.1641 billion, enhancing its capital strength and solvency, which is crucial for covering innovative drugs and supporting business expansion [8].